PRKD1, protein kinase D1, 5587

N. diseases: 171; N. variants: 19
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0740391
Disease: Middle Cerebral Artery Occlusion
Middle Cerebral Artery Occlusion 		0.010 Biomarker disease BEFREE Lower miR-31, higher PKD1 expressions, and activated JAK/STAT3 pathway were found in both the MCAO and OGD models. miR-31 could negatively target PKD1. 31517390 2020
CUI: C0948008
Disease: Ischemic stroke
Ischemic stroke 		0.010 Biomarker disease BEFREE The present study was conducted in order to investigate the effect of miR-31 on oxidative stress-induced neuronal injury in IS mice with the involvement of protein kinase D1 (PKD1) and the JAK/STAT3 pathway. 31517390 2020
CUI: C1334768
Disease: Minor Salivary Gland Adenocarcinoma
Minor Salivary Gland Adenocarcinoma 		0.010 GeneticVariation disease BEFREE Our results demonstrated that (1) PACs/CASGs are underpinned by genetic alterations affecting PRKD genes; (2) despite the associations between PAC and PRKD1 hotspot mutations and CASG and PRKD1/2/3 fusion, such distinction is not absolute; and (3) there is of a novel genotypic-phenotypic association whereby fusion-positive tumors are usually located in the base of the tongue, show papillary architecture and have a high risk of nodal metastasis. 31492931 2020
CUI: C0003864
Disease: Arthritis
Arthritis 		0.010 Biomarker disease BEFREE Our results suggest a possibility that ameliorating effects of Gö6976 on CIA may be due to its ability to inhibit TLR/IL-1R-activated PKD1, which might play an important role in proinflammatory responses in arthritis, and that PKD1 could be a therapeutic target for inflammatory arthritis. 31809526 2019
CUI: C0011860
Disease: Diabetes Mellitus, Non-Insulin-Dependent
Diabetes Mellitus, Non-Insulin-Dependent 		0.010 AlteredExpression disease BEFREE Pharmacological activation of PKD counters SINGD and delays the onset of T2D. 31346174 2019
CUI: C0018378
Disease: Guillain-Barre Syndrome
Guillain-Barre Syndrome 		0.010 Biomarker disease BEFREE PKD plays a critical role in mediating placental macrophage inflammatory activation in response to GBS infection. 30582878 2019
CUI: C0023903
Disease: Liver neoplasms
Liver neoplasms 		0.010 AlteredExpression group BEFREE In this study, we show that the ER stress inducers tunicamycin and thapsigargin lead to the activation of PKD1 in human prostate cancer PC-3 cells and in hepatoma HepG2 cells through a PKCδ-dependent mechanism. 31167779 2019
CUI: C0027051
Disease: Myocardial Infarction
Myocardial Infarction 		0.010 AlteredExpression disease BEFREE In the animal study, PKD inhibitor significantly suppressed platelets granule releasing and serum IGF1 levels (P < 0.05) in MI rats without affecting serum levels of vWF and sTF. 31607475 2019
CUI: C0029408
Disease: Degenerative polyarthritis
Degenerative polyarthritis 		0.010 Biomarker disease BEFREE Inflammatory stress caused by protein kinase D (PKD) plays a critical role in damaging chondrocytes and extracellular matrix (ECM) during osteoarthritis (OA). 31806974 2019
CUI: C0152013
Disease: Adenocarcinoma of lung (disorder)
Adenocarcinoma of lung (disorder) 		0.010 GeneticVariation disease BEFREE TP53 and PKD mutations were the two most frequently observed co-mutations in resected EGFR-mutated lung adenocarcinoma. 30820786 2019
CUI: C0521158
Disease: Recurrent tumor
Recurrent tumor 		0.010 Biomarker phenotype BEFREE Most importantly, pharmacological PKD inhibition in combination with paclitaxel synergistically decreased oncosphere and colony formation efficiency in vitro and tumor recurrence in vivo. 31745977 2019
CUI: C0585265
Disease: Hypoglossal Nerve Palsy
Hypoglossal Nerve Palsy 		0.010 GeneticVariation disease BEFREE Isolated hypoglossal nerve palsy from internal carotid artery dissection related to PKD-1 gene mutation. 31703639 2019
CUI: C0751815
Disease: Carotid Artery, Internal, Dissection
Carotid Artery, Internal, Dissection 		0.010 GeneticVariation disease BEFREE Isolated hypoglossal nerve palsy from internal carotid artery dissection related to PKD-1 gene mutation. 31703639 2019
CUI: C2020625
Disease: Group B Streptococcal Infection
Group B Streptococcal Infection 		0.010 Biomarker disease BEFREE PKD plays a critical role in mediating placental macrophage inflammatory activation in response to GBS infection. 30582878 2019
CUI: C2936719
Disease: Mechanical Allodynia
Mechanical Allodynia 		0.010 Biomarker phenotype BEFREE PKD and Gβγ inhibitors also attenuated protease-evoked mechanical allodynia in mice. 31142616 2019
CUI: C4083008
Disease: Guillain-Barre Syndrome, Familial
Guillain-Barre Syndrome, Familial 		0.010 Biomarker disease BEFREE PKD plays a critical role in mediating placental macrophage inflammatory activation in response to GBS infection. 30582878 2019
CUI: C0005684
Disease: Malignant neoplasm of urinary bladder
Malignant neoplasm of urinary bladder 		0.010 AlteredExpression disease BEFREE To further assess the role of PKD in bladder carcinoma, we examined the three PKD isoforms and found that PKD2 was highly expressed in eight bladder cancer cell lines and in urothelial carcinoma tissues from the TCGA database, and that short hairpin RNA (shRNA)-mediated knockdown of PKD2 dramatically reduced bladder cancer growth and invasion in vitro and in vivo, suggesting that the effect of the compound in bladder cancer is mediated through inhibition of PKD2. 29071385 2018
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.010 AlteredExpression disease BEFREE To further assess the role of PKD in bladder carcinoma, we examined the three PKD isoforms and found that PKD2 was highly expressed in eight bladder cancer cell lines and in urothelial carcinoma tissues from the TCGA database, and that short hairpin RNA (shRNA)-mediated knockdown of PKD2 dramatically reduced bladder cancer growth and invasion in vitro and in vivo, suggesting that the effect of the compound in bladder cancer is mediated through inhibition of PKD2. 29071385 2018
CUI: C0007097
Disease: Carcinoma
Carcinoma 		0.010 AlteredExpression group BEFREE CRT0066101, an inhibitor of PKD, has antitumor activity in multiple types of carcinomas. 29071385 2018
CUI: C0010606
Disease: Adenoid Cystic Carcinoma
Adenoid Cystic Carcinoma 		0.010 GeneticVariation disease BEFREE The PRKD1 E710D hotspot mutation is highly specific in separating polymorphous adenocarcinoma of the palate from adenoid cystic carcinoma and pleomorphic adenoma on FNA. 29266837 2018
CUI: C0015695
Disease: Fatty Liver
Fatty Liver 		0.010 GeneticVariation disease BEFREE Finally, deletion of PKD1 in adipocytes improves insulin sensitivity and ameliorates liver steatosis. 30389661 2018
CUI: C0019348
Disease: Herpes Simplex Infections
Herpes Simplex Infections 		0.010 Biomarker group BEFREE The present findings suggest that the PKD machinery not only affects the late stages of herpes simplex virus I egress but also modulates earlier steps, such as nuclear egress. 30232182 2018
CUI: C0020456
Disease: Hyperglycemia
Hyperglycemia 		0.010 GeneticVariation disease BEFREE Under a high-fat diet, deletion of PKD1 in β-cells worsened hyperglycemia, hyperinsulinemia, and glucose intolerance. 29038309 2018
CUI: C0026277
Disease: Mixed Salivary Gland Tumor
Mixed Salivary Gland Tumor 		0.010 GeneticVariation disease BEFREE None of the PA cases demonstrated PRKD1 mutations. 29266837 2018
CUI: C0028754
Disease: Obesity
Obesity 		0.010 Biomarker disease BEFREE Thus, depletion of PKD1 in adipocytes increases energy dissipation by several complementary mechanisms and might represent an attractive strategy to treat obesity and its related complications. 30389661 2018